Recombinant adenovirus vectors offer potential for human gene therapy because of their ability to transduce many tissues at high efficiency in vivo. The enthusiasm for use of these vectors has been tempered by a powerful immunologic response directed against vector containing cells because of the low level synthesis of vector derived antigens. The fact that adenovirus-mediated gene transfer is persistent in animals lacking antigen-dependent immunity establishes the need to produce a less antigenic vector. Dr. Kay and his colleagues recently developed a method for creating high titer adenovirus vectors that were devoid of vector genomic sequences responsible for producing the immune response. Unexpectedly, these deleted vectors, although efficient at gene transfer, with minimal or no toxicity, do not persist in vivo in immunocompetent or immunodeficient animals. This occurred because these deleted vectors could not replicate their genome in transduced cells in vitro and in vivo. Thus it is hypothesized that persistence of adenoviral DNA is inherently related to its ability to replicate. The major goals of this proposal are: 1) to determine the minimal number of adenovirus genes needed for stability and place these back into the vector to make a minimal vector that can persist; 2) determine the mechanism(s) allowing for vector genome persistence; 3) determine the acute toxicity and antigen-dependent immunological responses directed against the new vector; and 4) develop the deleted vector system to produce an integrating vector system. The results of these studies will have important implications for the development of adenoviruses for gene therapy.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Research Project (R01)
Project #
2R01DK049022-04
Application #
2016886
Study Section
Medical Biochemistry Study Section (MEDB)
Program Officer
Mckeon, Catherine T
Project Start
1994-09-30
Project End
1998-08-31
Budget Start
1997-09-01
Budget End
1998-08-31
Support Year
4
Fiscal Year
1997
Total Cost
Indirect Cost
Name
University of Washington
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
135646524
City
Seattle
State
WA
Country
United States
Zip Code
98195
Rauschhuber, Christina; Xu, Hui; Salazar, Felix H et al. (2008) Exploring gene-deleted adenoviral vectors for delivery of short hairpin RNAs and reduction of hepatitis B virus infection in mice. J Gene Med 10:878-89
Tward, Aaron D; Jones, Kirk D; Yant, Stephen et al. (2007) Distinct pathways of genomic progression to benign and malignant tumors of the liver. Proc Natl Acad Sci U S A 104:14771-6
Ehrhardt, Anja; Yant, Stephen R; Giering, Jeffery C et al. (2007) Somatic integration from an adenoviral hybrid vector into a hot spot in mouse liver results in persistent transgene expression levels in vivo. Mol Ther 15:146-56
Yant, Stephen R; Huang, Yong; Akache, Bassel et al. (2007) Site-directed transposon integration in human cells. Nucleic Acids Res 35:e50
Tolar, Jakub; O'shaughnessy, Matthew J; Panoskaltsis-Mortari, Angela et al. (2006) Host factors that impact the biodistribution and persistence of multipotent adult progenitor cells. Blood 107:4182-8
Ehrhardt, Anja; Engler, Jeffrey A; Xu, Hui et al. (2006) Molecular analysis of chromosomal rearrangements in mammalian cells after phiC31-mediated integration. Hum Gene Ther 17:1077-94
Tward, A D; Jones, K D; Yant, S et al. (2005) Genomic progression in mouse models for liver tumors. Cold Spring Harb Symp Quant Biol 70:217-24
Ehrhardt, Anja; Xu, Hui; Huang, Zan et al. (2005) A direct comparison of two nonviral gene therapy vectors for somatic integration: in vivo evaluation of the bacteriophage integrase phiC31 and the Sleeping Beauty transposase. Mol Ther 11:695-706
Ehrhardt, Anja; Xu, Hui; Dillow, Aaron M et al. (2003) A gene-deleted adenoviral vector results in phenotypic correction of canine hemophilia B without liver toxicity or thrombocytopenia. Blood 102:2403-11
Sclimenti, Christopher R; Neviaser, Andrew S; Baba, Edward J et al. (2003) Epstein-Barr virus vectors provide prolonged robust factor IX expression in mice. Biotechnol Prog 19:144-51

Showing the most recent 10 out of 39 publications